Fig. 4
From: PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

BKM120 inhibits PI3K but not mTOR pathway downstream effectors in LMS cells. Immunoblot demonstrating decreased levels of p-AKTS473, but not in p-4EBP1T37/46 in total lysates from SKLMS1 and STS39 cells treated with BKM120. SKLMS1 cells were treated for 72Â h at concentrations ranging from 0 to 1000Â nM/L. Total AKT, 4EBP1 and tubulin levels are shown for loading control